Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia

Leukemia

Volumn 27, Issue 8, 2013, Pages 1659-1665

  Logan, A C ^a   Zhang, B ^a   Narasimhan, B ^a   Carlton, V ^b   Zheng, J ^b   Moorhead, M ^b   Krampf, M R ^a   Jones, C D ^a   Waqar, A N ^a   Faham, M ^b   Zehnder, J L ^a   Miklos, D B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sequenta Inc   (United States)

Author keywords

allogeneic transplantation; chronic lymphocytic leukemia; highthroughput sequencing; minimal residual disease; relapse prediction

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN HEAVY CHAIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSENSUS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIMIT OF DETECTION; LYMPH NODE IRRADIATION; MALE; MINIMAL RESIDUAL DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REDUCED INTENSITY CONDITIONING; TUMOR VOLUME;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; RECURRENCE; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84881478607     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.52     Document Type: Article

References (38)

1. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 544-550.
2. Zenz T, Gribben JG, Hallek M, Dohner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012; 119: 4101-4107.
3. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
4. Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956-964. (Pubitemid 46672072)
5. Rawstron AC, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013; 27: 142-149.
6. Böttcher S, Ritgen M, Dreger P. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. Blood Rev 2011 25 91-96.
7. Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012 30 980-988.
8. Böttcher S, Ritgen M, Pott C, Bruggemann M, Raff T, Stilgenbauer S et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004; 18: 1637-1645. (Pubitemid 39386342)
9. Böttcher S, Stilgenbauer S, Busch R, Bruggemann M, Raff T, Pott C et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009; 23: 2007-2017.
10. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 2009; 1: 12ra23.
11. Logan AC, Gao H, Wang C, Sahaf B, Jones CD, Marshall EL et al. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lym-phocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci 2011; 108: 21194-21199.
12. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317. (Pubitemid 38072572)
13. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012; 120: 5173-5180.
14. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA et al. Protective conditioning for acute graft-versus-host disease. New Engl J Med 2005; 353: 1321-1331. (Pubitemid 41362700)
15. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009; 114: 1099-1109.
16. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012; 119: 6145-6154.
17. Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood 2012; 120: 4407-4417.
18. Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 241-253.
19. Ranheim EA, Jones CD, Zehnder JL. Sensitive detection of clonal immunoglobulin rearrangements in frozen and paraffin embedded tissues by polymerase chain reaction heteroduplex analysis. Diagn Mol Pathol 2000; 9: 177-183.
20. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone marrow transplant 1995; 15: 825-828.
21. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
22. Kaplan EI, Meier P. Nonparametric estimation from incomplete observation. J Am Statist Assoc 1958; 53: 457-481.
23. Team RDC. R: a language and environment for statistical computing. In R Foundation for Statistical Computing Vienna, Austria, 2010.
24. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2712-2716. (Pubitemid 17161803)
25. Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793-1798. (Pubitemid 27458621)
26. Dreger P, Ritgen M, Bottcher S, Schmitz N, Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Leukemia 2005; 19: 1135-1138. (Pubitemid 40945994)
27. Varghese AM, Rawstron AC, Hillmen P. Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment? Curr Hematol Malig Rep 2010; 5: 35-44.
28. Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116: 2438-2447.
29. Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009; 94: 654-662.
30. Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, Cullen MJ, Richards SJ et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004; 103: 2027-2031. (Pubitemid 38326216)
31. Ritgen M, Bottcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008; 22: 1377-1386. (Pubitemid 352006082)
32. Nabhan C, Coutre S, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br J Haematol 2007; 136: 379-392. (Pubitemid 46046296)
33. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alem-tuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-2979. (Pubitemid 46224116)
34. Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819-3829.
35. Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009; 144: 95-98.
36. Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563-4569. (Pubitemid 43801386)
37. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012: 88-96.
38. Kroger N, Bacher U, Bader P, Bottcher S, Borowitz MJ, Dreger P et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant 2010; 16: 1325-1346.